A new substance designed to treat Alzheimer’s disease offers very good prospects in terms of its effectiveness and is, so far, it appears to be safer, according to the conclusions that researchers have come.

Professor Arun Ghosh, the Purdue University in West Lafayette, Indiana, United States, designed the molecule, which is a potent inhibitor of beta-secretase, with unique features that ensure that targets only towards its goal and does not affect physiological processes that are necessary for good health.

the research team at arun ghosh

This molecule retains the properties of beta-secretase inhibitors prior to combat the disease, but is much less likely to cause harmful side effects. The degree of selectivity achieved by Ghosh and colleagues is unprecedented, so this substance is very promising as a potential medication for life usable by Alzheimer’s patients.

The new substance shows a selectivity of 7,000 times for target enzyme, a value well above the altitude of 1,000-fold selectivity attached to a substance that can be put toward a viable treatment for Alzheimer’s disease, and even exceeds the values selectivity achieved by beta-secretase inhibitors above.

The beta-secretase inhibitors, which may allow Alzheimer’s disease, in its early stages, are very promising. Several drugs that target molecular based have reached the stage of clinical trials, including one based on a previously designed Ghosh substance. These substances prevent the first step in a chain of events leading to the formation of amyloid plaques in the brain, which are fibrous proteins toxic accumulations believed to be the specific cause of the devastating symptoms of the disease.

Earlier versions of the new beta-secretase inhibitor could stop and even reverse the progression of amyloid plaques in tests on mice, but the strength and degree of selectivity are just two of the three pillars of a viable treatment of Alzheimer’s disease, such qualifies as Ghosh. You still have to see if this new substance has the third pillar, the ability to become an easily administered drug to pass through the blood brain barrier.

The blood-brain barrier is one of the strongest defensive barriers of the human body. It can be described as a labyrinth which prevents chemical toxins and viruses present in the blood reaches the brain. However, this robust security system also limits the ability of physicians to deliver drugs directly into the brain. That makes it harder to treat diseases like Alzheimer’s.

Many people in the world are suffering from Alzheimer’s disease. In the U.S. alone, it is estimated that the number of people affected is 5.1 million people.